{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:48:07Z","timestamp":1776743287557,"version":"3.51.2"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>APOE<\/jats:italic> genotypes are associated with ischemic heart disease (IHD), several other cardiovascular diseases and dementia. Previous studies have not comprehensively considered all genotypes, especially \u03b52\u03b52, nor associations by age and sex, although IHD incidence differs by sex. In the UK Biobank, including 391,992 white British participants, we compared effects of <jats:italic>APOE<\/jats:italic> genotypes on IHD and its risk factors. Compared to the \u03b53\u03b53 genotype, \u03b52\u03b52 was not clearly associated with IHD but was associated with lower plasma apolipoprotein B (apoB). The \u03b52\u03b53 genotype conferred lower IHD risk, systolic blood pressure (SBP), pulse pressure and plasma apoB than \u03b53\u03b53. \u03b53\u03b54 and \u03b54\u03b54 conferred higher IHD risk, higher pulse pressure and plasma apoB, but lower\u00a0glycated haemoglobin (HbA1c) than \u03b53\u03b53. The associations by age and sex were fairly similar, except \u03b52\u03b52 compared to \u03b53\u03b53 was marginally positively associated with IHD in the younger age group and nominally inversely associated with SBP in men. \u03b53\u03b54 compared to \u03b53\u03b53 was nominally positively associated with SBP in women. <jats:italic>APOE<\/jats:italic> genotypes affect IHD risk increasingly from \u03b52\u03b53, \u03b53\u03b53, \u03b53\u03b54 to \u03b54\u03b54, with similar patterns for pulse pressure and plasma apoB, but not for diabetes. Associations with blood pressure differed by sex. Greater understanding of products of <jats:italic>APOE<\/jats:italic> and their effects might generate targets of intervention.<\/jats:p>","DOI":"10.1038\/s41598-021-88256-x","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T10:05:37Z","timestamp":1619690737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Age and sex specific effects of APOE genotypes on ischemic heart disease and its risk factors in the UK Biobank"],"prefix":"10.1038","volume":"11","author":[{"given":"Mengyu","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie V.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man Ki","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Mary","family":"Schooling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"key":"88256_CR1","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","volume":"390","author":"GBD Causes of Death Collaborators","year":"2017","unstructured":"GBD Causes of Death Collaborators. Global regional, and national age-sex specific mortality for 264 causes of death, 1980\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390, 1151\u20131210. https:\/\/doi.org\/10.1016\/S0140-6736(17)32152-9 (2017).","journal-title":"Lancet"},{"key":"88256_CR2","volume-title":"The Global Economic Burden of Noncommunicable Diseases","author":"DE Bloom","year":"2011","unstructured":"Bloom, D. E. et al. The Global Economic Burden of Noncommunicable Diseases (World Economic Forum, 2011)."},{"key":"88256_CR3","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","volume":"380","author":"BF Voight","year":"2012","unstructured":"Voight, B. F. et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelianrandomisation study. Lancet (London, England) 380, 572\u2013580 (2012).","journal-title":"Lancet (London, England)"},{"key":"88256_CR4","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.cell.2012.03.001","volume":"148","author":"S Kathiresan","year":"2012","unstructured":"Kathiresan, S. & Srivastava, D. Genetics of human cardiovascular disease. Cell 148, 1242\u20131257. https:\/\/doi.org\/10.1016\/j.cell.2012.03.001 (2012).","journal-title":"Cell"},{"key":"88256_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3389\/fcvm.2018.00056","volume":"5","author":"L Shu","year":"2018","unstructured":"Shu, L., Blencowe, M. & Yang, X. Translating GWAS findings to novel therapeutic targets for coronary artery disease. Front. Cardiovasc. Med. 5, 56\u201356. https:\/\/doi.org\/10.3389\/fcvm.2018.00056 (2018).","journal-title":"Front. Cardiovasc. Med."},{"key":"88256_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/bmb\/lds009","volume":"102","author":"DI Swerdlow","year":"2012","unstructured":"Swerdlow, D. I., Holmes, M. V., Harrison, S. & Humphries, S. E. The genetics of coronary heart disease. Br. Med. Bull. 102, 59\u201377. https:\/\/doi.org\/10.1093\/bmb\/lds009 (2012).","journal-title":"Br. Med. Bull."},{"key":"88256_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1161\/CIR.0000000000000366","volume":"133","author":"D Mozaffarian","year":"2016","unstructured":"Mozaffarian, D. et al. executive summary: heart disease and stroke statistics\u20142016 update. Circulation 133, 447\u2013454. https:\/\/doi.org\/10.1161\/CIR.0000000000000366 (2016).","journal-title":"Circulation"},{"key":"88256_CR8","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jamainternmed.2019.7194","volume":"180","author":"D Bartz","year":"2020","unstructured":"Bartz, D. et al. Clinical advances in sex- and gender-informed medicine to improve the health of all: a review. JAMA Intern. Med. 180, 574\u2013583. https:\/\/doi.org\/10.1001\/jamainternmed.2019.7194 (2020).","journal-title":"JAMA Intern. Med."},{"key":"88256_CR9","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1001\/jamacardio.2016.1326","volume":"1","author":"S Sidney","year":"2016","unstructured":"Sidney, S. et al. Recent trends in cardiovascular mortality in the United States and public health goals. JAMA Cardiol. 1, 594\u2013599. https:\/\/doi.org\/10.1001\/jamacardio.2016.1326 (2016).","journal-title":"JAMA Cardiol."},{"key":"88256_CR10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1001\/jamacardio.2016.1348","volume":"1","author":"DM Lloyd-Jones","year":"2016","unstructured":"Lloyd-Jones, D. M. Slowing progress in cardiovascular mortality rates: you reap what you sow. JAMA Cardiol. 1, 599\u2013600. https:\/\/doi.org\/10.1001\/jamacardio.2016.1348 (2016).","journal-title":"JAMA Cardiol."},{"key":"88256_CR11","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.3390\/ijms20184513","volume":"20","author":"T Li","year":"2019","unstructured":"Li, T. et al. Discontinued drugs for the treatment of cardiovascular disease from 2016 to 2018. Int. J. Mol. Sci. 20, 4513. https:\/\/doi.org\/10.3390\/ijms20184513 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"88256_CR12","doi-asserted-by":"publisher","first-page":"e258","DOI":"10.1371\/journal.pmed.0030258","volume":"3","author":"M Reilly","year":"2006","unstructured":"Reilly, M. & Rader, D. J. Apolipoprotein E and coronary disease: a puzzling paradox. PLoS Med. 3, e258. https:\/\/doi.org\/10.1371\/journal.pmed.0030258 (2006).","journal-title":"PLoS Med."},{"key":"88256_CR13","doi-asserted-by":"publisher","first-page":"12222","DOI":"10.18632\/aging.103405","volume":"12","author":"CL Kuo","year":"2020","unstructured":"Kuo, C. L., Pilling, L. C., Atkins, J. L., Kuchel, G. A. & Melzer, D. ApoE e2 and aging-related outcomes in 379,000 UK Biobank participants. Aging (Albany NY) 12, 12222\u201312233. https:\/\/doi.org\/10.18632\/aging.103405 (2020).","journal-title":"Aging (Albany NY)"},{"key":"88256_CR14","doi-asserted-by":"publisher","first-page":"102954","DOI":"10.1016\/j.ebiom.2020.102954","volume":"59","author":"AL Lumsden","year":"2020","unstructured":"Lumsden, A. L., Mulugeta, A., Zhou, A. & Hypp\u00f6nen, E. Apolipoprotein E (APOE) genotype-associated disease risks: a phenome-wide, registry-based, case-control study utilising the UK Biobank. EBioMedicine 59, 102954. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102954 (2020).","journal-title":"EBioMedicine"},{"key":"88256_CR15","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/iub.1314","volume":"66","author":"MC Phillips","year":"2014","unstructured":"Phillips, M. C. Apolipoprotein E isoforms and lipoprotein metabolism. IUBMB Life 66, 616\u2013623. https:\/\/doi.org\/10.1002\/iub.1314 (2014).","journal-title":"IUBMB Life"},{"key":"88256_CR16","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1515\/cclm-2016-0145","volume":"55","author":"QR Zhao","year":"2017","unstructured":"Zhao, Q. R., Lei, Y. Y., Li, J., Jiang, N. & Shi, J. P. Association between apolipoprotein E polymorphisms and premature coronary artery disease: a meta-analysis. Clin. Chem. Lab. Med. 55, 284\u2013298. https:\/\/doi.org\/10.1515\/cclm-2016-0145 (2017).","journal-title":"Clin. Chem. Lab. Med."},{"key":"88256_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/gerona\/gly174","volume":"74","author":"P Sebastiani","year":"2018","unstructured":"Sebastiani, P. et al. APOE alleles and extreme human longevity. J. Gerontol. Ser. A 74, 44\u201351. https:\/\/doi.org\/10.1093\/gerona\/gly174 (2018).","journal-title":"J. Gerontol. Ser. A"},{"key":"88256_CR18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1530\/eje.0.1470503","volume":"147","author":"I Zofkov\u00e1","year":"2002","unstructured":"Zofkov\u00e1, I., Zaj\u00edckov\u00e1, K., Hill, M. & Hor\u00ednek, A. Apolipoprotein E gene determines serum testosterone and dehydroepiandrosterone levels in postmenopausal women. Eur. J. Endocrinol. 147, 503\u2013506. https:\/\/doi.org\/10.1530\/eje.0.1470503 (2002).","journal-title":"Eur. J. Endocrinol."},{"key":"88256_CR19","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1016\/s0140-6736(17)32462-5","volume":"390","author":"CM Schooling","year":"2017","unstructured":"Schooling, C. M. Practical applications of evolutionary biology in public health. Lancet 390, 2246. https:\/\/doi.org\/10.1016\/s0140-6736(17)32462-5 (2017).","journal-title":"Lancet"},{"key":"88256_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/ajpa.21298","volume":"143","author":"DT Eisenberg","year":"2010","unstructured":"Eisenberg, D. T., Kuzawa, C. W. & Hayes, M. G. Worldwide allele frequencies of the human apolipoprotein E gene: climate, local adaptations, and evolutionary history. Am. J. Phys. Anthropol. 143, 100\u2013111. https:\/\/doi.org\/10.1002\/ajpa.21298 (2010).","journal-title":"Am. J. Phys. Anthropol."},{"key":"88256_CR21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/s0197-4580(99)00053-6","volume":"20","author":"CE Finch","year":"1999","unstructured":"Finch, C. E. & Sapolsky, R. M. The evolution of Alzheimer disease, the reproductive schedule, and apoE isoforms. Neurobiol. Aging 20, 407\u2013428. https:\/\/doi.org\/10.1016\/s0197-4580(99)00053-6 (1999).","journal-title":"Neurobiol. Aging"},{"key":"88256_CR22","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/s0197-4580(99)00081-0","volume":"20","author":"RW Mahley","year":"1999","unstructured":"Mahley, R. W. & Rall, S. C. Jr. Is epsilon4 the ancestral human apoE allele?. Neurobiol. Aging 20, 429\u2013430. https:\/\/doi.org\/10.1016\/s0197-4580(99)00081-0 (1999).","journal-title":"Neurobiol. Aging"},{"key":"88256_CR23","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1001\/jama.298.11.1300","volume":"298","author":"AM Bennet","year":"2007","unstructured":"Bennet, A. M. et al. Association of apolipoprotein e genotypes with lipid levels and coronary risk. JAMA 298, 1300\u20131311. https:\/\/doi.org\/10.1001\/jama.298.11.1300 (2007).","journal-title":"JAMA"},{"key":"88256_CR24","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.4103\/0366-6999.156803","volume":"128","author":"Y Zhang","year":"2015","unstructured":"Zhang, Y., Tang, H.-Q., Peng, W.-J., Zhang, B.-B. & Liu, M. Meta-analysis for the association of apolipoprotein E \u03b52\/\u03b53\/\u03b54 polymorphism with coronary heart disease. Chin. Med. J. (Engl.) 128, 1391\u20131398. https:\/\/doi.org\/10.4103\/0366-6999.156803 (2015).","journal-title":"Chin. Med. J. (Engl.)"},{"key":"88256_CR25","doi-asserted-by":"publisher","first-page":"e104608","DOI":"10.1371\/journal.pone.0104608","volume":"9","author":"H Xu","year":"2014","unstructured":"Xu, H. et al. Meta-analysis of apolipoprotein E gene polymorphism and susceptibility of myocardial infarction. PLoS ONE 9, e104608\u2013e104608. https:\/\/doi.org\/10.1371\/journal.pone.0104608 (2014).","journal-title":"PLoS ONE"},{"key":"88256_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3912175","author":"M Xu","year":"2016","unstructured":"Xu, M. et al. Apolipoprotein E gene variants and risk of coronary heart disease: a meta-analysis. Biomed. Res. Int. https:\/\/doi.org\/10.1155\/2016\/3912175 (2016).","journal-title":"Biomed. Res. Int."},{"key":"88256_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.gene.2018.06.097","volume":"675","author":"J Shi","year":"2018","unstructured":"Shi, J. et al. Association between ApoE polymorphism and hypertension: a meta-analysis of 28 studies including 5898 cases and 7518 controls. Gene 675, 197\u2013207. https:\/\/doi.org\/10.1016\/j.gene.2018.06.097 (2018).","journal-title":"Gene"},{"key":"88256_CR28","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3967\/bes2019.104","volume":"32","author":"DW Chen","year":"2019","unstructured":"Chen, D. W., Shi, J. K., Li, Y., Yang, Y. & Ren, S. P. Association between ApoE polymorphism and type 2 diabetes: a meta-analysis of 59 studies. Biomed. Environ. Sci. 32, 823\u2013838. https:\/\/doi.org\/10.3967\/bes2019.104 (2019).","journal-title":"Biomed. Environ. Sci."},{"key":"88256_CR29","first-page":"104","volume":"42","author":"E Boerwinkle","year":"1988","unstructured":"Boerwinkle, E. & Utermann, G. Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism. Am. J. Hum. Genet. 42, 104\u2013112 (1988).","journal-title":"Am. J. Hum. Genet."},{"key":"88256_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/nu10101524","author":"BA Griffin","year":"2018","unstructured":"Griffin, B. A. et al. APOE4 genotype exerts greater benefit in lowering plasma cholesterol and apolipoprotein B than wild type (E3\/E3), after replacement of dietary saturated fats with low glycaemic index carbohydrates. Nutrients https:\/\/doi.org\/10.3390\/nu10101524 (2018).","journal-title":"Nutrients"},{"key":"88256_CR31","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/ije\/dyt034","volume":"42","author":"TA Khan","year":"2013","unstructured":"Khan, T. A. et al. Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals. Int. J. Epidemiol. 42, 475\u2013492. https:\/\/doi.org\/10.1093\/ije\/dyt034 (2013).","journal-title":"Int. J. Epidemiol."},{"key":"88256_CR32","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/archneurol.2012.1070","volume":"69","author":"HD Soares","year":"2012","unstructured":"Soares, H. D. et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch. Neurol. 69, 1310\u20131317. https:\/\/doi.org\/10.1001\/archneurol.2012.1070 (2012).","journal-title":"Arch. Neurol."},{"key":"88256_CR33","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1161\/01.atv.16.10.1250","volume":"16","author":"PW Wilson","year":"1996","unstructured":"Wilson, P. W., Schaefer, E. J., Larson, M. G. & Ordovas, J. M. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. ArteriosclerThromb. Vasc. Biol. 16, 1250\u20131255. https:\/\/doi.org\/10.1161\/01.atv.16.10.1250 (1996).","journal-title":"ArteriosclerThromb. Vasc. Biol."},{"key":"88256_CR34","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.mad.2004.06.008","volume":"125","author":"F Licastro","year":"2004","unstructured":"Licastro, F. et al. The concomitant presence of polymorphic alleles of interleukin-1beta, interleukin-6 and apolipoprotein E is associated with an increased risk of myocardial infarction in elderly men. Results from a pilot study. Mech. Ageing Dev. 125, 575\u2013579. https:\/\/doi.org\/10.1016\/j.mad.2004.06.008 (2004).","journal-title":"Mech. Ageing Dev."},{"key":"88256_CR35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ajmg.10142","volume":"107","author":"BT Heijmans","year":"2002","unstructured":"Heijmans, B. T. et al. Association of APOE epsilon2\/epsilon3\/epsilon4 and promoter gene variants with dementia but not cardiovascular mortality in old age. Am. J. Med. Genet. 107, 201\u2013208. https:\/\/doi.org\/10.1002\/ajmg.10142 (2002).","journal-title":"Am. J. Med. Genet."},{"key":"88256_CR36","doi-asserted-by":"publisher","first-page":"e001956","DOI":"10.1161\/circgen.117.001956","volume":"11","author":"JV Zhao","year":"2018","unstructured":"Zhao, J. V. & Schooling, C. M. Coagulation factors and the risk of ischemic heart disease: a mendelian randomization study. Circ. GenomPrecis. Med. 11, e001956. https:\/\/doi.org\/10.1161\/circgen.117.001956 (2018).","journal-title":"Circ. GenomPrecis. Med."},{"key":"88256_CR37","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/jama.2018.20045","volume":"321","author":"BA Ference","year":"2019","unstructured":"Ference, B. A. et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA 321, 364\u2013373. https:\/\/doi.org\/10.1001\/jama.2018.20045 (2019).","journal-title":"JAMA"},{"key":"88256_CR38","doi-asserted-by":"publisher","first-page":"e1003062","DOI":"10.1371\/journal.pmed.1003062","volume":"17","author":"TG Richardson","year":"2020","unstructured":"Richardson, T. G. et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. PLoS Med. 17, e1003062. https:\/\/doi.org\/10.1371\/journal.pmed.1003062 (2020).","journal-title":"PLoS Med."},{"key":"88256_CR39","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jama.2017.11467","volume":"318","author":"BA Ference","year":"2017","unstructured":"Ference, B. A. et al. Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA 318, 947\u2013956. https:\/\/doi.org\/10.1001\/jama.2017.11467 (2017).","journal-title":"JAMA"},{"key":"88256_CR40","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow, C. et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 12, e1001779\u2013e1001779. https:\/\/doi.org\/10.1371\/journal.pmed.1001779 (2015).","journal-title":"PLoS Med."},{"key":"88256_CR41","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","volume":"562","author":"C Bycroft","year":"2018","unstructured":"Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203\u2013209. https:\/\/doi.org\/10.1038\/s41586-018-0579-z (2018).","journal-title":"Nature"},{"key":"88256_CR42","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/s41588-018-0205-x","volume":"50","author":"E Evangelou","year":"2018","unstructured":"Evangelou, E. et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat. Genet. 50, 1412\u20131425. https:\/\/doi.org\/10.1038\/s41588-018-0205-x (2018).","journal-title":"Nat. Genet."},{"key":"88256_CR43","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/s0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent, C. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267\u20131278. https:\/\/doi.org\/10.1016\/s0140-6736(05)67394-1 (2005).","journal-title":"Lancet"},{"key":"88256_CR44","unstructured":"UK Biobank GWAS results, http:\/\/www.nealelab.is\/uk-biobank\/ (2018)."},{"key":"88256_CR45","unstructured":"Ageing and health, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ageing-and-health (2018)."},{"key":"88256_CR46","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1745-9125.1998.tb01268.x","volume":"36","author":"R Paternoster","year":"1998","unstructured":"Paternoster, R., Brame, R., Mazerolle, P. & Piquero, A. Using the correct statistical test for the equality of regression coefficients. Criminology 36, 859\u2013866. https:\/\/doi.org\/10.1111\/j.1745-9125.1998.tb01268.x (1998).","journal-title":"Criminology"},{"key":"88256_CR47","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/s0531-5565(00)00171-6","volume":"35","author":"BT Heijmans","year":"2000","unstructured":"Heijmans, B. T., Westendorp, R. G. & Slagboom, P. E. Common gene variants, mortality and extreme longevity in humans. Exp. Gerontol. 35, 865\u2013877. https:\/\/doi.org\/10.1016\/s0531-5565(00)00171-6 (2000).","journal-title":"Exp. Gerontol."},{"key":"88256_CR48","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/0076-6879(86)28109-4","volume":"128","author":"VI Zannis","year":"1986","unstructured":"Zannis, V. I. Genetic polymorphism in human apolipoprotein E. Methods Enzymol. 128, 823\u2013851. https:\/\/doi.org\/10.1016\/0076-6879(86)28109-4 (1986).","journal-title":"Methods Enzymol."},{"key":"88256_CR49","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/MED.0000000000000316","volume":"24","author":"C Koopal","year":"2017","unstructured":"Koopal, C., Marais, A. D. & Visseren, F. L. J. Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder. Curr. Opin. Endocrinol. Diabetes Obes. 24, 133\u2013139 (2017).","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"88256_CR50","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ymgme.2010.03.008","volume":"100","author":"PG Anthopoulos","year":"2010","unstructured":"Anthopoulos, P. G., Hamodrakas, S. J. & Bagos, P. G. Apolipoprotein E polymorphisms and type 2 diabetes: a meta-analysis of 30 studies including 5423 cases and 8197 controls. Mol. Genet. Metab. 100, 283\u2013291. https:\/\/doi.org\/10.1016\/j.ymgme.2010.03.008 (2010).","journal-title":"Mol. Genet. Metab."},{"key":"88256_CR51","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1038\/s41467-018-05512-x","volume":"9","author":"C Yao","year":"2018","unstructured":"Yao, C. et al. Genome-wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. Nat. Commun. 9, 3268 (2018).","journal-title":"Nat. Commun."},{"key":"88256_CR52","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1073\/pnas.80.1.283","volume":"80","author":"ML Blue","year":"1983","unstructured":"Blue, M. L., Williams, D. L., Zucker, S., Khan, S. A. & Blum, C. B. Apolipoprotein E synthesis in human kidney, adrenal gland, and liver. Proc. Natl. Acad. Sci. U.S.A. 80, 283\u2013287. https:\/\/doi.org\/10.1073\/pnas.80.1.283 (1983).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"88256_CR53","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/bjsm.2003.000199","volume":"38","author":"F Hartgens","year":"2004","unstructured":"Hartgens, F., Rietjens, G., Keizer, H. A., Kuipers, H. & Wolffenbuttel, B. H. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br. J. Sports Med. 38, 253\u2013259. https:\/\/doi.org\/10.1136\/bjsm.2003.000199 (2004).","journal-title":"Br. J. Sports Med."},{"key":"88256_CR54","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1161\/circulationaha.117.027966","volume":"136","author":"AJ Vallejo-Vaz","year":"2017","unstructured":"Vallejo-Vaz, A. J. et al. Low-density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg\/dL or above: analyses from the WOSCOPS (west of scotland coronary prevention study) 5-year randomized trial and 20-year observational follow-up. Circulation 136, 1878\u20131891. https:\/\/doi.org\/10.1161\/circulationaha.117.027966 (2017).","journal-title":"Circulation"},{"key":"88256_CR55","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/s0140-6736(12)61190-8","volume":"380","author":"PM Ridker","year":"2012","unstructured":"Ridker, P. M., Pradhan, A., MacFadyen, J. G., Libby, P. & Glynn, R. J. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 380, 565\u2013571. https:\/\/doi.org\/10.1016\/s0140-6736(12)61190-8 (2012).","journal-title":"Lancet"},{"key":"88256_CR56","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/nejm199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N. Engl. J. Med. 341, 709\u2013717. https:\/\/doi.org\/10.1056\/nejm199909023411001 (1999).","journal-title":"N. Engl. J. Med."},{"key":"88256_CR57","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/s0140-6736(07)60108-1","volume":"369","author":"WJ Elliott","year":"2007","unstructured":"Elliott, W. J. & Meyer, P. M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369, 201\u2013207. https:\/\/doi.org\/10.1016\/s0140-6736(07)60108-1 (2007).","journal-title":"Lancet"},{"key":"88256_CR58","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard, B. G. et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J. 34, 3478\u20133490. https:\/\/doi.org\/10.1093\/eurheartj\/eht273 (2013).","journal-title":"Eur. Heart J."},{"key":"88256_CR59","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jama.2015.1206","volume":"313","author":"J Besseling","year":"2015","unstructured":"Besseling, J., Kastelein, J. J., Defesche, J. C., Hutten, B. A. & Hovingh, G. K. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA 313, 1029\u20131036. https:\/\/doi.org\/10.1001\/jama.2015.1206 (2015).","journal-title":"JAMA"},{"key":"88256_CR60","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/jama.2015.1275","volume":"313","author":"D Preiss","year":"2015","unstructured":"Preiss, D. & Sattar, N. Does the LDL receptor play a role in the risk of developing type 2 diabetes?. JAMA 313, 1016\u20131017. https:\/\/doi.org\/10.1001\/jama.2015.1275 (2015).","journal-title":"JAMA"},{"key":"88256_CR61","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41431-017-0078-y","volume":"26","author":"Y Ghaleb","year":"2018","unstructured":"Ghaleb, Y. et al. Usefulness of the genetic risk score to identify phenocopies in families with familial hypercholesterolemia?. Eur. J. Hum. Genet. 26, 570\u2013578. https:\/\/doi.org\/10.1038\/s41431-017-0078-y (2018).","journal-title":"Eur. J. Hum. Genet."},{"key":"88256_CR62","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1741-7015-11-57","volume":"11","author":"CM Schooling","year":"2013","unstructured":"Schooling, C. M., Au Yeung, S. L., Freeman, G. & Cowling, B. J. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med. 11, 57\u201357. https:\/\/doi.org\/10.1186\/1741-7015-11-57 (2013).","journal-title":"BMC Med."},{"key":"88256_CR63","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/13685538.2018.1468429","volume":"21","author":"K Groti","year":"2018","unstructured":"Groti, K., \u017duran, I., Antoni\u010d, B., For\u0161nari\u010d, L. & Pfeifer, M. The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male 21, 158\u2013169. https:\/\/doi.org\/10.1080\/13685538.2018.1468429 (2018).","journal-title":"Aging Male"},{"key":"88256_CR64","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/ije\/dys223","volume":"42","author":"KJ Rothman","year":"2013","unstructured":"Rothman, K. J., Gallacher, J. E. & Hatch, E. E. Why representativeness should be avoided. Int. J. Epidemiol. 42, 1012\u20131014. https:\/\/doi.org\/10.1093\/ije\/dys223 (2013).","journal-title":"Int. J. Epidemiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88256-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88256-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88256-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T07:32:34Z","timestamp":1670052754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88256-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["88256"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-88256-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,29]]},"assertion":[{"value":"19 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9229"}}